GLP-1 Peptide Atlas, by Delfa

← Trials/Trial dossier/NCT00154401

CompletedPhase 2

Effect of Liraglutide on Blood Glucose Control in Subjects With Type 2 Diabetes

Effect of Liraglutide on Glycaemic Control in Subjects With Type 2 Diabetes.

Lead sponsor

Novo Nordisk A/S

Asset

Liraglutide

Subcutaneous · GLP-1 agonist

Listed sites

Recruiting sites

—

Enrollment

177

actual

Study population

Type 2 diabetes

Key I/E criterion

•HbA1c ≤10%

Primary endpoint

•HbA1c, change

Footprint

Where this trial recruits

Site locations as reported to ClinicalTrials.gov. Site count is not enrollment count; per-site enrollment is not available from source.

Identifiers

Registered as

NCT IDNCT00154401

Org study IDNN2211-1571

Timeline

Milestones

Study first posted2005-09-12estimated

Last update posted2017-01-25estimated

Study start2005-01 (month precision)

Primary completion2005-10actual (month precision)

Study completion2005-10actual (month precision)

Assets

Investigational agents

Liraglutide

Study populations

Who this study enrolls

Type 2 diabetes

Eligibility

Who can enroll

Minimum age18 Years

SexAll

Healthy volunteersNot accepted

Inclusion criteria

•Subjects diagnosed with type 2 diabetes mellitus and treated with either diet or single oral drug therapy

•Diet treated subjects: 7.5% < HbA1c < 10%

•Single oral drug therapy subjects: 7.0% < HbA1c < 9.5%

•Body Mass Index (BMI): max 40 kg/m^2

Exclusion criteria

•Subjects treated with thiazolidinediones or insulin

•Subjects with any serious medical conditions

Endpoints (4)

What's being measured

Protocol endpoints and posted registry outcome measures, grouped into outcome categories. Composite endpoints show their component event types. Standard codes (LOINC, SNOMED CT) are shown where available.

Coverage by outcome category

Glycemic / diabetes

Weight & body composition

Safety / tolerability / PK

Weight & body composition

1 endpoint

Secondary/protocol endpoint

Body weight after 14 weeks.

descriptive, improvement

Glycemic / diabetes

2 endpoints

Primary/protocol endpoint

HbA1c

Time frame:after 14 weeks treatment

HbA1c, change

change from baseline, improvement

LOINC 4548-4

Secondary/protocol endpoint

Glycaemic control parameters (fasting plasma glucose, glucose profiles) after 14 weeks.

Fasting glucose, change

change from baseline, improvement

LOINC 1558-6

Safety / tolerability / PK

1 endpoint

Secondary/protocol endpoint

Safety and tolerability

descriptive

Publications (5)

Bibliography

Records linked to this trial through ClinicalTrials.gov references, PubMed NCT search, and curated study seeds. 'Canonical' marks design/result papers; others are registry references or candidates.

Registry references + supporting bibliography

Is there a link between liraglutide and pancreatitis? A post hoc review of pooled and patient-level data from completed liraglutide type 2 diabetes clinical trials.
Diabetes care2015 Jun (month)PMID25504028doi:10.2337/dc13-1210via CT.gov reference
Beneficial effects of once-daily liraglutide, a human glucagon-like peptide-1 analogue, on cardiovascular risk biomarkers in patients with Type 2 diabetes.
Diabetic medicine : a journal of the British Diabetic Association2008 Sep (month)PMID19183322doi:10.1111/j.1464-5491.2008.02484.xvia CT.gov reference
Patient-reported rating of gastrointestinal adverse effects during treatment of type 2 diabetes with the once-daily human GLP-1 analogue, liraglutide.
Diabetes, obesity & metabolism2008 Jul (month)PMID18435773doi:10.1111/j.1463-1326.2008.00861.xvia CT.gov reference
Liraglutide, a once-daily human GLP-1 analogue, improves pancreatic B-cell function and arginine-stimulated insulin secretion during hyperglycaemia in patients with Type 2 diabetes mellitus.
Diabetic medicine : a journal of the British Diabetic Association2008 Feb (month)PMID18201212doi:10.1111/j.1464-5491.2007.02333.xvia CT.gov reference
Liraglutide, a long-acting human glucagon-like peptide-1 analog, given as monotherapy significantly improves glycemic control and lowers body weight without risk of hypoglycemia in patients with type 2 diabetes.
Diabetes care2007 Jun (month)PMID17372153doi:10.2337/dc06-2593via CT.gov reference + pubmed nct search

Provenance

Sources

Trial identity, design, statusClinicalTrials.gov API v2

Snapshot dateJuly 1, 2026

Endpoint classificationDelfa endpoint taxonomy v2 (May 13, 2026)

Results tableno registry results posted yet

Trial facts come from public ClinicalTrials.gov records. Endpoint categories are Delfa's classification of those records, not a ClinicalTrials.gov field. All figures reflect the July 1, 2026 snapshot.